We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Arbutus Biopharma Corporation | NASDAQ:ABUS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.03 | 1.12% | 2.71 | 2.50 | 3.35 | 2.85 | 2.70 | 2.71 | 683,613 | 05:00:00 |
• | Q2 2019 Press Release: | August 5, 2019 at 7:30 a.m. ET |
• | Q2 2019 Conference Call: | August 5, 2019 at 8:45 a.m. ET |
• | Domestic Dial-In Number: | (866) 393-1607 |
• | International Dial-In Number: | (914) 495-8556 |
• | Conference ID Number: | 2098024 |
A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID 2098024.
About ArbutusArbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.
Contact Information
InvestorsWilliam H. Collier President and CEO Phone: 604-419-3200 Email: ir@arbutusbio.com MediaPam Murphy Investor Relations Consultant Phone: 604-419-3200 Email: ir@arbutusbio.com
1 Year Arbutus Biopharma Chart |
1 Month Arbutus Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions